CeQur develops and commercializes simple drug delivery devices for people with diabetes. Their 3-day bolus insulin delivery device, CeQur Simplicity, is extremely slim and discreet, allowing for easy administration of insulin without the need to step away from friends. The device is FDA cleared for adults requiring insulin and is currently in a pilot launch stage in 2021. CeQur Simplicity has been tested in three clinical studies and has high patient satisfaction over daily injections. CeQur is headquartered in Horw, Switzerland, with operations in Marlborough, Massachusetts.